Small molecule · Inhibitor of ataxia telangiectasia and Rad3 related protein kinase (ATR) · developed by Aprea Therapeutics
ATRN-119 (mosipasertib) is an orally bioavailable inhibitor of the ATR kinase, a DNA damage response protein. It binds ATR and blocks downstream CHK1 phosphorylation, disrupting DNA damage checkpoint activation and repair and inducing tumor cell apoptosis. It is being studied in HPV-positive oropharyngeal squamous cell carcinoma and other HPV-associated carcinomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07578467 | Phase 1/2 | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Not yet recruiting | APRE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HPV (Human Papillomavirus)-Associated CarcinomaHPV Associated CancersHPV Positive Oropharyngeal Squamous Cell CarcinomaOropharyngeal HPV Squamous Cell CarcinomaSquamous Cell Carcinoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the APRE page.
See APRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
APRE catalysts and pipeline →